Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.57 |
| ▸ | ITGAV | P06756 | 19/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.57 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6162794 | 1.00 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6696125 | 0.99 | ITGB3 (0.56) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL3052806 | 0.97 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6697749 | 0.96 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| Trifluoroacetic Acid SCHEMBL6163896 | 0.96 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6165576 | 0.96 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6694974 | 0.95 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| Trifluoroacetic Acid SCHEMBL6167633 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6693162 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6694759 | 0.94 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254133-B9 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2005-09-07 | — | — | EP | claimed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| EP-1254133-B1 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2005-04-20 | — | — | EP | claimed |
| EP-1474162-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | claimed |
| US-20040138284-A1 | Indol-3-yl derivatives | WIESNER MATTHIAS | 2004-07-15 | — | — | US | claimed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | claimed |
| EP-1411926-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | claimed |
| US-20040029788-A1 | Methods and compositions for the treatment of diseases of the eye | MERCK PATENT GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| EP-1381382-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GmbH (DE) | 2004-01-21 | — | — | EP | claimed |
| WO-2003068253-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | WO | claimed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | claimed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | claimed |
| WO-2002041910-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | claimed |
| US-7648959-B2 | Methods and compositions for the treatment of diseases of the eye | MERCK PATENT GMBH (DE) | 2010-01-19 | — | — | US | disclosed |
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002041910-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB3 5/4885ITGAV 3/4885ITGB1 6/4885 |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | IGF1R, IDO1, ITGB3 | ITGB3 3/4885ITGAV 67/4885ITGB1 4/4885 |
| US-20040138284-A1 | Indol-3-yl derivatives | ITGB3, ITGB1, IGF1R | ITGB3 1/4885ITGAV 35/4885ITGB1 2/4885 |
| US-20040029788-A1 | Methods and compositions for the treatment of diseases of the eye | ITGA5, ITGAV, ITGB3 | ITGB3 3/4885ITGAV 2/4885ITGB1 7/4885 |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB3 4/4885ITGAV 3/4885ITGB1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.